JUBLINGREA Jubilant Ingrevia Q4 FY26 results (Jan–Mar 2026) and concall
Jubilant Ingrevia reported a strong Q4 FY26, achieving its highest quarterly revenue and EBITDA in 14 quarters, driven by healthy double-digit growth in both top and bottom lines. The company saw robust performance in Specialty Chemicals and Nutrition, with effective management of Middle East disruptions and strategic acquisitions. While facing some challenges in acetic acid pricing and the slow agrochemical market, the company remains confident in sustained growth, particularly in Specialty Chemicals and Nutrition, supported by its Pinnacle Journey initiatives and CDMO pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 12.2%, net profit up 16.2% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,057 | 1,051 | 1,038 | 1,121 | 1,051 −1% | 1,179 +12% |
| EBITDA | 138 | 147 | 142 | 135 | 126 −9% | 163 +11% |
| Net profit | 69 | 74 | 75 | 69 | 47 −32% | 86 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
